Audio

• Finding a better, longer-lasting fix in opioid overdose

  December 10, 2025

  The opioid crisis may not be front and center anymore, but it’s raging still. A major problem is that overdose-reversal drugs don’t last long enough to help users who opt out of hospital treatment after they are revived. Elysium Therapeutics Inc. CEO Greg Sturmer talks with Randy Osborne about his firm’s candidate for a solution to the medical and societal problem. The NIH – which has been helpful to Elysium since the company’s founding – the FDA, and others are working to advance a longer-lasting reversal agent. Experiments already done with approved reversers, as well as computer modeling that’s been used by regulators previously, will help in the push, Sturmer said.

  Download transcript
• Trying this at home: Bioxcel steps closer to an sNDA for Igalmi

  August 27, 2025

  Bioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment. Vimal Mehta, Bioxcel CEO, talks about the potential with Lee Landenberger in the latest BioWorld Insider podcast.

  Watch the video version of this podcast here.

  Download transcript
• Preventing opioid overdoses with a smart patch

  June 04, 2023

  Brad Holden, CEO of Resilient Lifescience, explains how the device works for overdoses as well as other potential applications for this new technology.

  Download transcript